
Opinion|Videos|April 3, 2024
Improving Long-Term Outlook: CT Scans and Underdiagnosis of Bronchiectasis
Pamela J. McShane, MD, discusses the long-term outcome of patients with bronchiectasis and emphasizes the crucial role of radiographic imaging in diagnosing the disease.
Advertisement
Episodes in this series

Advertisement
Related to this article

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
3
Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
4
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
5



